8-K: Coherus BioSciences Director Stolper to Depart, Board Realigns Class Assignments

Mark D. Stolper will not seek re-election to the Coherus BioSciences Board of Directors, prompting a reclassification of board member assignments.

Summary

• Mark D. Stolper, a member of the Board of Directors of Coherus BioSciences, Inc., has announced his intention not to stand for re-election at the 2025 Annual Meeting of Stockholders.
• His decision was not due to any disagreement with the company, and he will continue to serve on the Board until the election of directors at the 2025 Annual Meeting.
• Following his departure, Mr. Stolper is expected to provide consulting support to the company through December 31, 2026.
• The Board has decreased the number of directors that can serve on the Board to nine directors effective upon the departure of Mr. Stolper from the Board.
• To balance membership among the three classes of directors, Rita A. Karachun was reclassified from Class II to Class I, and Michael Ryan was reclassified from Class III to Class II.
• These reclassifications were effective April 23, 2025, and were done to comply with the company's Amended and Restated Certificate of Incorporation.
• The current composition of the Board is now three Class I directors, four Class II directors and three Class III directors.

Sentiment

Score: 7

Explanation: The announcement is neutral, detailing a planned board member departure and subsequent board rebalancing. The continued consulting role of the departing member is a slightly positive aspect.

Positives

• Mark Stolper will continue to provide valuable support to the Company on a consulting basis through December 31, 2026, ensuring a smooth transition and continued access to his expertise.

Future Outlook

Following his departure from the Board, Mr. Stolper is expected to continue to provide valuable support to the Company on a consulting basis through December 31, 2026.

Industry Context

Changes in board composition are common in the biotech industry as companies evolve and adapt to changing market conditions and strategic priorities.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: The board changes could influence investor sentiment, depending on their view of the departing and remaining directors.
• Employees: The changes are unlikely to have a direct impact on employees.
• Customers: The changes are unlikely to have a direct impact on customers.

Next Steps

• Election of directors at the 2025 Annual Meeting.
• Mr. Stolper's transition to a consulting role.

Key Dates

Keywords

Board of Directors, Re-election, Board Reclassification, Corporate Governance, Coherus BioSciences